gram-negative

(redirected from Gram-negative bacterial infections)
Also found in: Dictionary, Thesaurus, Medical.

gram-negative

[′gram¦neg·əd·iv]
(microbiology)
Of bacteria, decolorizing and staining with the counterstain when treated with Gram's stain.
References in periodicals archive ?
* A review of the Gram-Negative Bacterial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Approximately 700,000 people worldwide die of drug-resistant infections every year and this number is expected to increase significantly in the future.1 Serious bacterial infections, and in particular Gram-negative bacterial infections, have been identified by the WHO as a global public health priority.2
Cidara also is leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections.
The Potentiator Platform molecules are designed to treat Gram-negative bacterial infections.
The company said Zavicefta (ceftazidime-avibactam) is a fixed-dose combination antibacterial that was developed to treat serious Gram-negative bacterial infections. It consists of a combination of avibactam and ceftazidime - a third-generation antipseudomonal cephalosporin with a well-established efficacy and safety profile.
CAZ-AVI (ceftazidime-avibactam) is an investigational antibiotic being developed to treat serious Gram-negative bacterial infections. It consists of ceftazidime, a third-generation, antipseudomonal cephalosporin, that is an established treatment for serious Gram-negative bacterial infections, and avibactam, a next generation, non-beta lactam beta-lactamase inhibitor.
However, endotoxemia in liver transplant recipients has been associated with graft failure and a high mortality rate (4,5), and in gram-negative bacterial infections, the physiologic effects of endotoxin may persist after adequate antimicrobial drug treatment.
Serious bacterial infections, and in particular Gram-negative bacterial infections, have been identified by the World Health Organization (WHO) as a global public health priority.
Cidara also is leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of multi-drug resistant Gram-negative bacterial infections.
The grant will fund the continued research and development of Cidara's Cloudbreak antibody-drug conjugate platform to identify novel immunotherapy agents for the treatment and prevention of serious and life-threatening multi-drug resistant gram-negative bacterial infections in high-risk patient populations.
Pfizer's (NYSE:PFE) novel combination antibiotic for patients with serious Gram-negative bacterial infections, Zavicefta, has been launched in the UK and Germany, the company announced on Tuesday.
meningosepticum infections are rare, accurate diagnosis is important because the species is usually resistant to multiple antibiotics, especially to those (including extended-spectrum [Beta]-lactam agents and aminoglycosides) typically prescribed for treatment of aerobic, gram-negative bacterial infections. Moreover, epidemics may occur, and a death rate as high as 55% has been reported in a nursery outbreak (8,9).

Full browser ?